Article in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Eibhlin GogginsDivision of Nephrology, Center for Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States.ORCID 0000-0001-7952-7726
Yanjun XieDepartment of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, United States.
Yi HuangDepartment of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, United States.ORCID 0009-0003-3029-7343
Carson BrantleyDivision of Nephrology, Center for Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States.ORCID 0009-0007-5341-8821
Junlan YaoDivision of Nephrology, Center for Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States.ORCID 0009-0004-2411-742X
Sylvia CechovaDivision of Nephrology, Center for Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States.ORCID 0000-0001-7631-7707
John A HossackDepartment of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, United States.ORCID 0000-0003-1299-0745
Mark D OkusaDivision of Nephrology, Center for Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States.ORCID 0000-0002-0801-0532
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
Sphingolipids in Acute Kidney Injury and Disease ProgressionR01DK085259 · NIDDK · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2010 to 2023
$5.0M
Neuroimmune Regulation of Acute Kidney InjuryR01DK123248 · NIDDK · UNIVERSITY OF VIRGINIA · PI Mark Douglas Okusa · 2019 to 2026
$3.3M
Ultrasound for Non-Invasive Prevention of Acute Kidney InjuryR01DK105133 · NIDDK · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2015 to 2019
$2.4M
Accelerated Low Dose Thrombolytic Catheter Directed SonothrombolysisR01HL141752 · NHLBI · UNIVERSITY OF VIRGINIA · PI HOSSACK, JOHN A · 2018 to 2021
$2.0M
IGNITE KUH NRSA Training CoreTL1DK132771 · NIDDK · UNIVERSITY OF VIRGINIA · PI PORTILLA, DIDIER · 2021 to 2025
$1.9M
Integrated Virginia Research Training Centers in KUH (IGNITE KUH)U2CDK129500 · NIDDK · UNIVERSITY OF VIRGINIA · PI SHARMA, RAHUL · 2021 to 2025
$1.4M
Proof of concept and feasibility in humans for pulsed ultrasound treatment to reduce inflammation and risk of AKIR01DK137937 · NIDDK · UNIVERSITY OF VIRGINIA · PI Mark Douglas Okusa, Mitchell H. Rosner · 2024 to 2026
$942k
The University of Virginia Kidney Technology Development Research Education Program (VA K-TUTOR)R25DK124918 · NIDDK · UNIVERSITY OF VIRGINIA · PI GUILFORD, WILLIAM H, OKUSA, MARK DOUGLAS · 2020 to 2024
$699k
MBF Bioscience and Zeiss Microscope System for Stereology and Tissue MorphologyS10RR026799 · NCRR · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2010 to 2010
$278k
Effect of Pulsed Splenic Ultrasound on delaying Chronic Kidney Disease Progression through a Neuroimmune Mechanism.F30DK138782 · NIDDK · UNIVERSITY OF VIRGINIA · PI Eibhlin Goggins · 2024 to 2026
$132k
HHS | National Institutes of Health (NIH) 1S10RR026799HHS | National Institutes of Health (NIH) T32GM007267HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL141752HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1F30DK138782-01A1HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1U2CDK129500/1TL1DK132771HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK123248HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R25DK124918NCRR NIH HHS S10 RR026799NHLBI NIH HHS R01 HL141752NIDDK NIH HHS F30 DK138782NIDDK NIH HHS R01 DK085259NIDDK NIH HHS R01 DK105133NIDDK NIH HHS R01 DK123248NIDDK NIH HHS R01 DK137937NIDDK NIH HHS R25 DK124918NIDDK NIH HHS TL1 DK132771NIDDK NIH HHS U2C DK129500NIGMS NIH HHS T32 GM007267
6 · The paper itself
Abstract
Acute kidney injury (AKI) is a devastating condition with major complications including death and, in some cases, progression to chronic kidney disease (CKD). We have previously shown that pulsed ultrasound (pUS) can reduce kidney ischemia-reperfusion injury (IRI) by activating the cholinergic anti-inflammatory pathway. The efficacy of a spleen-targeted pUS regimen in AKI of other etiologies and its long-term impact are unclear. Using a new spleen-targeted US approach, pUS was delivered to male mice 24 h before folic acid (FA), lipopolysaccharide, or bilateral kidney IRI. Mice were monitored and assessed for markers of inflammation, renal function, and kidney fibrosis. When compared with sham, mice that received spleen-targeted pUS had reduced plasma TNFα and blood urea nitrogen (BUN) after sepsis-associated AKI, reduced plasma creatinine, and BUN after kidney IRI and reduced plasma creatinine, BUN, and kidney fibrosis after FA administration. pUS-treated mice displayed reduced myeloid cell infiltration to the kidneys after FA and IRI. In sham-treated mice, markers associated with ongoing maladaptive repair including
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pulsed ultrasound targeted to the spleen mitigates against kidney injury and promotes kidney repair. · full record | OpenQuestion